Citations

Clear

1320 citation(s) found for "Nguyen, Vi".

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study
Cohen, Jonathon B. , Shah, Nirav N. , Eyre, Toby A. , Ujjani, Chaitra S. , Kim, Won Seog , Alencar, Alvaro J. , Lewis, David , Woyach, Jennifer A. , Maddocks, Kami J. , Seymour, John F. , Nagai, Hirokazu, Fakhri, Bita , Hernandez‐Ilizaliturri, Francisco J. , Kumar, Anita , Munir, Talha, Tsai, Donald E. , Balbas, Minna, Liu, Bin , Ruppert, Amy S. , Nguyen, Bastien , Wang, Michael , Fakhri, Bita , Jurczak, Wojciech , Zinzani, Pier Luigi , Cheah, Chan Y. , Koh, Youngil , Nasta, Sunita , Flinn, Ian W. , Tessoulin, Benoit , Ma, Shuo , Patel, Krish , Wang, Yucai , Rhodes, Joanna , Tam, Constantine S. , Vose, Julie M. , Hoffmann, Marc Steven , Zelenetz, Andrew D. , Roeker, Lindsey E.

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 981-981

10.1182/blood-2023-181627 Get It

Background: Despite the efficacy of covalent (c) Bruton tyrosine kinase inhibitors (BTKi) in R/R MCL, disease relapse arises through evolution of resistance mechanisms or development of cBTKi intolerance. Pirtobrutinib, a highly selective, non-covalent (reversible) BTKi has favorable oral pharmacology that enables continuous BTK inhibition throughout the daily dosing interval regardless of the intrinsic rate of BTK turnover. Pirtobrutinib is the first BTKi to demonstrate durable efficacy following prior cBTKi therapy in heavily pre-treated R/R MCL and was well-tolerated with a low frequency of treatment discontinuation due to toxicity (Wang et al., JCO, 2023). Pirtobrutinib is approved in the USA to treat relapsed or refractory MCL after at least two lines of systemic therapy including a prior cBTKi. Here, we report updated results of pirtobrutinib therapy in all patients (pts), including those with biologically high-risk R/R MCL with a median survival follow-up of 24.2 months (range, 18.2-29.8). Methods: Pts with R/R MCL received pirtobrutinib monotherapy in the multicenter Phase 1/2 BRUIN trial (NCT03740529). Efficacy was assessed in all cBTKi pre-treated pts, as well as in cBTKi treatment-naïve pts. Key endpoints included overall response rate (ORR) as assessed by independent review committee per Lugano 2014 criteria, duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. Pts were included across the dose escalation range and expansion (25-300 mg/day) with 93% (n=141) receiving at least one dose of 200 mg/day, the FDA-approved dose. A data cut of 05 May 2023 was utilized. Results: Among all 152 pts with R/R MCL who received a prior cBTKi, the median age was 70 years (range, 46-88), and 52% had intermediate-risk and 28.3% had high-risk sMIPI scores. Median prior lines of therapy were 3 (range, 1-9), including an anti-CD20 antibody (96.7%), chemotherapy (90.1%), immunomodulator (17.1%), stem cell transplant (21.7%), BCL-2 inhibitor (15.8%), CAR-T cell therapy (8.6%), and PI3K inhibitor (3.9%). Among pts with high-risk biomarker data available, 30/60 (50%) had TP53 mutations and 45/63 (71%) had a Ki-67 index of ≥30%. The ORR for cBTKi pre-treated pts was 49.3% (95% CI, 41.1-57.6), including 15.8% complete responses (n=24) and 33.6% partial responses (n=51), whilst cBTKi naïve pts (n=14) had an ORR of 85.7% (95% CI, 57.2-98.2). The ORR among 128 pts who had discontinued a prior cBTKi due to PD and 21 pts who had discontinued for toxicity/other reasons was 43.0% and 90.5%, respectively. Among the 75 responding cBTKi pre-treated pts, the median DOR was 21.6 months (95% CI, 9.2-27.2) at a median follow-up of 24 months. The 18- and 24-month DOR rates were 51.9% (95% CI, 37-64.8) and 38.9% (95% CI, 22.7-54.8), respectively. ORR and DOR by high-risk subgroups (including blastoid/pleomorphic variants, Ki-67 index ≥30%, and TP53 mutations) are shown in Table 1. The 18- and 24-month DOR rates among 12 responding cBTKi naïve pts were both 90.0% (95% CI, 47.3-98.5). The median PFS and OS for cBTKi pre-treated pts was 5.6 months (95% CI, 5.3-9.2), and 23.5 months (95% CI, 17.1-NE), respectively. In the MCL cohort (n=166), the most frequent treatment-emergent adverse events (TEAEs) were fatigue (31.9%), diarrhea (22.3%), and dyspnea (17.5%). The most common Grade ≥3 TEAE was neutropenia/neutrophil count decreased (13.3%) and the rate of Grade ≥3 infections was (19.9%). Grade ≥3 hemorrhage/hematoma (2.4%) and all-grade atrial fibrillation/flutter (3.6%) were infrequent. Overall, 8 pts (5%) had treatment-related AEs leading to dose reductions and 5 (3%) had treatment-related AEs leading to pirtobrutinib discontinuation. Conclusion: Pirtobrutinib continues to demonstrate durable efficacy and a favorable safety profile in heavily pre-treated R/R MCL pts with prior cBTKi therapy. High ORRs were observed in pts who had PD on a prior cBTKi, and in pts with high-risk disease features including blastoid/pleomorphic variants, elevated Ki-67 index, and TP53 mutations.
Alfred Washington Adson: Perspectives on Intracranial Neurosurgery and the Responsibilities of the Neurosurgeon
Nguyen, Brandon A., Parikh, Parth , Nguyen, Andrew , Stonnington, Henry O. , Bendok, Bernard R. , Quiñones‐Hinojosa, Alfredo , Spinner, Robert J. , Meyer, Fredric B. , Bydon, Mohamad , Nguyen, Brandon , Singh, Rohin

Mayo Clinic

Neurosurgery | November 16, 2023 | Volume: 94 | Issue: 4 | Pages: 875-881

10.1227/neu.0000000000002758 | PMID 38497807 Get It

In a period when the budding field of neurosurgery was believed to have little promise, Dr Alfred Washington Adson founded and led the first neurosurgical department at Mayo Clinic. He was not without reservations—surgical intervention for neurological conditions was rarely pursued because of poor outcomes and high complication rates, and Dr Adson acknowledged his early concerns about the future of neurosurgery in his memoirs. However, his education, mentorship, his training, and his first neurosurgical cases helped to shape the impact he ultimately had on the field and his legacy as a neurosurgeon. Dr Adson trained with several renowned Mayo general surgeons, notably his mentor Dr Emil Beckman, whose desire for operative precision shaped Dr Adson's drive to develop his own skills as a surgeon. Two years into his residency, he became the youngest staff surgeon and was tasked with managing the neurosurgical cases at Mayo. The five neurosurgical cases overseen by Dr Adson in the next year illuminated the opportunity for neurosurgery to drastically improve the lives of patients. Dr Adson, given the option of continuing as either a general surgeon or a neurosurgeon, ultimately chose to pursue neurosurgery. This article seeks to provide a historical perspective on the neurosurgeon Dr Alfred Washington Adson using primary and secondary accounts from the Mayo archives, highlighting his contributions to the early understanding of intracranial pathology and how his early experiences as a trainee developed into a personal passion for self-improvement, education, and advocacy for health care in America.
PATH-23. CLINICOPATHOLOGIC ANALYSIS OF NOVEL METHYLATION CLUSTERS OF IDH-WILDTYPE DIFFUSE GLIOMAS
Aldape, Kenneth , Abdullaev, Zied , Turakulov, Rust , Camelo‐Piragua, Sandra , Pytel, Peter , Borys, Ewa, Nix, Stephen, Sloan, Emily A. , Phillips, Kester A., Serafini, Luciano Neder, Trejo‐Lopez, Jorge , Mendez, Joe , Christensen, Brock C. , Colman, Howard , Nguyen, Aivi, Li, Rong , Mandell, James W. , Clarke, Matthew , Mackay, Alan , Helgager, Jeffrey , López, Giselle Y. , Gregorio, Joao Vitor Antunes Marques, Sterman, Hugo , Nasrallah, MacLean P. , Singh, Omkar , Andreiuolo, Felipe , Costa, Felipe D’Almeida , Zhang, Daniel Y. , Fernandes, Igor, Eberhart, Charles G. , Smith-Cohn, Matthew , Neill, Stewart G. , Macaulay, Robert , Colman, Howard , Giannini, Caterina , Kessler, Tobias , Wick, Wolfgang , Jones, Chris , Lee, Han, Perry, Arie , Ahmadian, Saman Seyed , Haeri, Mohammad , Wang, Shih‐Hsiu J. , Dahiya, Sonika , Souza, Andrea Silveira de , Gregorio, João Vitor Antunes Marques , Aboud, Orwa

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v172-v172

10.1093/neuonc/noad179.0653 Get It

Abstract Methylation profiling of brain tumors has revealed novel clusters whose biological and clinical significance is unknown. These include three entities termed by the 12.5 version of the Heidelberg methylation classifier as adult-type diffuse high grade glioma, IDH-wildtype, subtype B (HGG_B), subtype E (HGG_E), and subtype F (HGG_F). We have identified 75 cases belonging to these groups: HGG_B (25 cases, 32% female), HGG_E (40 cases, 42% female), and HGG_F (18 cases, 33% female). Although originally characterized as “adult-type,” we find that 70% of HGG_E cases are pediatric, with a median age at diagnosis of 11 years. HGG_B cases are predominantly seen in young adults, and HGG_F in older adults. The histology varies among methylation classes, with HGG_B cases demonstrating high-grade, predominantly astrocytic, morphology, while HGG_E cases demonstrate high-grade glial histology with distinct nuclear features, and HGG_F cases show highly infiltrative but lower grade glial morphology. Patient outcome data obtained to date shows a collective median survival exceeding 5 years, suggesting re-consideration of the proposed grading for these tumors. MGMT promoter methylation differs across the HGG_B (0%), HGG_E (12%), and HGG_F (0%) subtypes. Mutational analyses show enrichment of TERT promoter mutations in the HGG_F group, while HGG_E samples are enriched for tumors with POLE mutations and elevated tumor mutation burden. HGG_E tumors show epigenetic similarity to pediatric high-grade diffuse gliomas (pedHGG_RTK1A); we therefore propose that HGG_E be considered a pediatric-type HGG. HGG_B tumors show demographic and genomic similarities to high-grade astrocytomas with piloid features, including a subset of cases with CDKN2A/2B loss and ATRX mutation. HGG_F separate into two groups dictated by brain location, and despite the presence of TERT promoter mutations, appear distinct from GBMs. Overall, our work represents an initial effort to understand the morphologic, genomic and clinical characteristics of these previously uncharacterized subtypes of gliomas.
Author response: Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study
Vinayak, Shaveta , Sun, Tianyi , Kuderer, Nicole M. , Balmaceda, Nicole , Bilen, Mehmet Asım , Bindal, Poorva , Blau, Sibel , Bodin, Brianne E, Borno, Hala T. , Choi, Horyun, Deeken, John F. , Edwin, Natasha, Feldman, Lawrence , Flora, Daniel , Galsky, Matthew D. , Gonzalez, Cyndi J, Grivas, Petros , Gupta, Shilpa , Haynam, Marcy , Heilman, Hannah, Jhawar, Sachin R, Kaklamani, Virginia , Klein, Elizabeth J. , Koshkin, Vadim S. , Kulkarni, Amit , Kwon, Daniel H. , Lammers, Philip E. , Lathrop, Kate, Lewis, Mark A. , Lopes, Gilbert de Lima, Makower, Della , Mansoor, Abdul-Hai, Mashru, Sandeep H., McKay, Rana R. , Messing, Ian , Mico, Vasil, Nadkarni, Rajani, Namburi, Swathi, Nguyen, Ryan H, Nonato, Taylor K., Park, Kyu, Patel, Jaymin , Patel, Kanishka G. , Peppercorn, Jeffrey , Polimera, Hyma , Puc, Matthew , Reid, Sonya , Riess, Jonathan W. , Rivera, Donna R. , Russ, Atlantis Dawn, Schapira, Lidia , Shanahan, M Kelly, Smits, Melissa, Streckfuss, Mitrianna, Thompson, Michael A, Tolaney, Sara M. , Weissmann, Lisa B., Wilson, Grace, Wulff‐Burchfield, Elizabeth , French, Benjamin , Accordino, Melissa , Nagaraj, Gayathri , Khaki, Ali Raza , Aboulafia, David M. , Acoba, Jared David , Awosika, Joy A. , Bakouny, Ziad , Bao, Ting , Bashir, Babar , Berg, Stephanie , Castellano, Cecilia A. , Desai, Aakash , Friese, Christopher R. , Hershman, Dawn L. , Hwang, Clara , Jani, Chinmay , Jhawar, Sachin R, Joshi, Monika , Knox, Natalie, Labaki, Chris , Li, Xuanyi , Lyman, Gary H , Markham, Merry Jennifer , Nguyen, Ryan H, O’Connor, Tracey L. , Panagiotou, Orestis A. , Rao, Yuan James , Razavi, Pedram , Robson, Mark E. , Rose, Suzanne J. , Shah, Pankil , Shapiro, Lauren C. , Stover, Daniel G. , Tachiki, Lisa , Thompson, Michael A, Wotman, Michael T. , Mishra, Sanjay , Warner, Jeremy L. , Lustberg, Maryam B. , Shah, Dimpy P.

Mayo Clinic

No container title available | November 10, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.82618.sa2 Get It

Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity
Couch, Steven M., Wester, Sara T. , Fowler, Brian , Liu, Catherine Y., Subramanian, Prem S. , Tang, Rosa A. , Nguyen, Quang T., Maamari, Robi N. , Karon, M , Douglas, Raymond S , Karon, Michael , Nguyen, Quang T, Ugradar, Shoaib , Hsu, Kate, Stan, Marius N.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | November 5, 2023 | Volume: 109 | Issue: 1 | Pages: 25-35

10.1210/clinem/dgad637 | PMID 37925673 Get It

AbstractContextEarly inflammatory thyroid eye disease (TED) can lead to symptomatic chronic disease, including disabling proptosis. Teprotumumab, an insulin-like growth factor-1 receptor (IGF-1R) inhibitor, previously demonstrated efficacy in acute, high-inflammation TED trials.ObjectiveWe present data from the first placebo-controlled trial with teprotumumab in chronic/low disease activity TED.MethodsThis randomized double-masked, placebo-controlled trial, conducted at 11 US centers, enrolled adult participants with TED duration of 2 to 10 years, Clinical Activity Score (CAS) ≤ 1 or no additional inflammation or progression in proptosis/diplopia for ≥1 year, proptosis ≥3 mm from before TED and/or from normal, euthyroid/mildly hypo/hyperthyroid, no prior teprotumumab, and no steroids within 3 weeks of baseline. Patients received (2:1) intravenous teprotumumab or placebo once every 3 weeks (total 8 infusions). The primary endpoint was proptosis (mm) improvement at Week 24. Adverse events (AEs) were assessed.ResultsA total of 62 (42 teprotumumab and 20 placebo) patients were randomized. At Week 24, least squares mean (SE) proptosis improvement was greater with teprotumumab (−2.41 [0.228]) than with placebo (−0.92 [0.323]), difference −1.48 (95% CI −2.28, −0.69; P = .0004). Proportions of patients with AEs were similar between groups. Hyperglycemia was reported in 6 (15%) vs 2 (10%) and hearing impairment in 9 (22%) vs 2 (10%) with teprotumumab and placebo, respectively. AEs led to discontinuation in 1 teprotumumab (left ear conductive hearing loss with congenital anomaly) and 1 placebo patient (infusion-related). There were no deaths.ConclusionTeprotumumab significantly improved proptosis vs placebo in longstanding/low inflammation TED, demonstrating efficacy regardless of disease duration/activity. The safety profile was comparable to that previously reported.
European Stroke Organisation (ESO) guidelines on Primary Angiitis of the Central Nervous System (PACNS)
Pascarella, Rosario , Antonenko, Katherina, Boysson, Hubert de , Kargiotis, Odysseas , Nguyen, Thanh N. , Rice, Claire M , Schmidt‐Pogoda, Antje , Strbian, Daniel , De Boysson, Hubert , Kargiotis, Odysseas , Nguyen, Thanh N , Rice, Claire M , Strbian, Daniel , Zedde, Marialuisa , Pascarella, Rosario , Boulouis, Grégoire , Giannini, Caterina , Heldner, Mirjam R. , Salvarani, Carlo , Hussain, Salman , Zedde, Marialuisa

Mayo Clinic

European Stroke Journal | October 30, 2023 | Volume: 8 | Issue: 4 | Pages: 842-879

10.1177/23969873231190431 | PMID 37903069 Get It

The European Stroke Organisation (ESO) guideline on Primary Angiitis of the Central Nervous System (PACNS), developed according to ESO standard operating procedures (SOP) and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology, was elaborated to assist clinicians in the diagnostic and treatment pathway of patients with PACNS in their decision making. A working group involving vascular neurologists, neuroradiologists, rheumatologists, a neuropathologist and a methodologist identified 17 relevant clinical questions; these were addressed according to the patient/population, intervention, comparison and outcomes (PICO) framework and systematic literature reviews were performed. Notably, each PICO was addressed with respect to large vessel (LV)-PACNS and small vessel (SV)-PACNS. Data to answer many questions were scarce or lacking and the quality of evidence was very low overall, so, for some PICOs, the recommendations reflect the ongoing uncertainty. When the absence of sufficient evidence precluded recommendations, Expert Consensus Statements were formulated. In some cases, this applied to interventions in the diagnosis and treatment of PACNS which are embedded widely in clinical practice, for example patterns of cerebrospinal fluid (CSF) and Magnetic Resonance Imaging (MRI) abnormalities. CSF analysis for hyperproteinorrachia and pleocytosis does not have evidence supporting their use as diagnostic tools. The working group recommended that caution is employed in the interpretation of non-invasive vascular imaging due to lack of validation and the different sensitivities in comparison with digital subtraction angiography (DSA) and histopathological analyses. Moreover, there is not a neuroimaging pattern specific for PACNS and neurovascular issues are largely underreported in PACNS patients. The group’s recommendations on induction and maintenance of treatment and for primary or secondary prevention of vascular events also reflect uncertainty due to lack of evidence. Being uncertain the role and practical usefulness of current diagnostic criteria and being not comparable the main treatment strategies, it is suggested to have a multidisciplinary team approach in an expert center during both work up and management of patients with suspected PACNS. Highlighting the limitations of the currently accepted diagnostic criteria, we hope to facilitate the design of multicenter, prospective clinical studies and trials. A standardization of neuroimaging techniques and reporting to improve the level of evidence underpinning interventions employed in the diagnosis and management of PACNS. We anticipate that this guideline, the first comprehensive European guideline on PACNS management using GRADE methodology, will assist clinicians to choose the most effective management strategy for PACNS.
First pass effect as an independent predictor of functional outcomes in medium vessel occlusions: An analysis of an international multicenter study
Radu, Răzvan Alexandru , Costalat, Vincent , Fahed, Robert , Ghozy, Sherief , Shaikh, Hamza , Khalife, Jane , Abdalkader, Mohamad , Klein, Piers , Nguyen, Thanh N. , Heit, Jeremy J. , Regenhardt, Robert W. , Diestro, Jose Danilo Bengzon , Cancelliere, Nicole M , Amllay, Abdelaziz , Dusart, Anne , Bellante, Flavio, Rouchaud, Aymeric , Puri, Ajit S., Dyzmann, Christian , Kan, Peter , Colasurdo, Marco , Berge, Jérôme , Barreau, Xavier , Nedelcu, Simona , Henninger, Nils , Kyheng, Maéva , Marotta, Thomas R. , Stapleton, Christopher J. , Rabinov, James D. , Dofuku, Shogo , Tan, Benjamin Yong‐Qiang , Salazar‐Marioni, Sergio , Capirossi, Carolina , Mowla, Ashkan , Tjoumakaris, Stavropoula I, Khandelwal, Priyank , Biswas, Arundhati , Clarençon, Frédéric , Elhorany, Mahmoud , Premat, Kévin , Valente, Iacopo , Filipe, João Pedro , Varela, Ricardo , Quintero‐Consuegra, Miguel , Gonzalez, Nestor R. , Möhlenbruch, Markus , Tancredi, Illario , Yedavalli, Vivek , Chervak, Lina , Aziz, Yasmin , Stracke, Christian Paul , Hecker, Constantin , Hsieh, Cheng‐Yang , Liebeskind, David S. , Alexandre, Andrea , Faizy, Tobias D. , Patel, Aman B. , Lubicz, Boris , Guenego, Adrien , Klein, Piers , Nguyen, Thanh N , Heit, Jeremy J , Sweid, Ahmad , Bellante, Flavio , Forestier, Géraud , Kühn, Anna Luisa , Marnat, Gaultier , Ota, Takahiro , Dofuku, Shogo , Yeo, Leonard Ll , Salazar-Marioni, Sergio , Jabbour, Pascal , Gonzalez, Nestor R , Möhlenbruch, Markus A , Jesser, Jessica , Aziz, Yasmin , Faizy, Tobias D , Liebeskind, David S. , Ghozy, Sherief , Diestro, Jose Danilo B , Regenhardt, Robert W , Alexandru Radu, Răzvan , Fahed, Robert , Yedavalli, Vivek S , Cancelliere, Nicole M , Rouchaud, Aymeric , Colasurdo, Marco , Hecker, Constantin , Henninger, Nils , Tan, Benjamin Yq , Alexandre, Andrea M , Mowla, Ashkan , Varela, Ricardo , Siegler, James E. , Naamani, Kareem El , Meyer, Lukas , Forestier, Géraud , Saleme, Suzana , Mounayer, Charbel , Fiehler, Jens , Kühn, Anna Luisa , Puri, Ajit S , Sibon, Igor , Martinez-Gutierrez, Juan Carlos , Sheth, Sunil A , Renieri, Leonardo , Tjoumakaris, Stavropoula , Jabbour, Pascal , Khandelwal, Priyank , Pedicelli, Alessandro , Schiphorst, Adrien ter , Harker, Pablo , Gory, Benjamin , Killer-Oberpfalzer, Monika , Griessenauer, Christoph J. , Thomas, Ajith J , Weyland, Charlotte S. , Mendes Pereira, Vitor , Dmytriw, Adam A.

Mayo Clinic

European Stroke Journal | October 27, 2023 | Volume: 9 | Issue: 1 | Pages: 114-123

10.1177/23969873231208276 | PMID 37885243 Get It

Abstract Introduction: First pass effect (FPE), achievement of complete recanalization (mTICI 2c/3) with a single pass, is a significant predictor of favorable outcomes for endovascular treatment (EVT) in large vessel occlusion stroke (LVO). However, data concerning the impact on functional outcomes and predictors of FPE in medium vessel occlusions (MeVO) are scarce. Patients and Methods: We conducted an international retrospective study on MeVO cases. Multivariable logistic modeling was used to establish independent predictors of FPE. Clinical and safety outcomes were compared between the two study groups (FPE vs non-FPE) using logistic regression models. Good outcome was defined as modified Rankin Scale 0–2 at 3 months. Results: Eight hundred thirty-six patients with a final mTICI ⩾ 2b were included in this analysis. FPE was observed in 302 patients (36.1%). In multivariable analysis, hypertension (aOR 1.55, 95% CI 1.10–2.20) and lower baseline NIHSS score (aOR 0.95, 95% CI 0.93–0.97) were independently associated with an FPE. Good outcomes were more common in the FPE versus non-FPE group (72.8% vs 52.8%), and FPE was independently associated with favorable outcome (aOR 2.20, 95% CI 1.59–3.05). 90-day mortality and intracranial hemorrhage (ICH) were significantly lower in the FPE group, 0.43 (95% CI, 0.25–0.72) and 0.55 (95% CI, 0.39–0.77), respectively. Conclusion: Over 2/3 of patients with MeVOs and FPE in our cohort had a favorable outcome at 90 days. FPE is independently associated with favorable outcomes, it may reduce the risk of any intracranial hemorrhage, and 3-month mortality.
A conceptual framework for nomenclatural stability and validity of medically important fungi: a proposed global consensus guideline for fungal name changes supported by ABP, ASM, CLSI, ECMM, ESCMID-EFISG, EUCAST-AFST, FDLC, IDSA, ISHAM, MMSA, and MSGERC
Walsh, Thomas J. , Ahmed, Sarah , Alastruey‐Izquierdo, Ana , Alexander, Barbara D. , Arendrup, Maiken Cavling , Babady, Esther , Balada-Llasat, Joan-Miquel, Borman, Andrew M. , Colgrove, Robert C. , Cornely, Oliver A. , Fuller, Jeff, Gibas, Connie Fe C., Glasgow, Heather, Gräser, Yvonne , Groll, Andreas H. , Haase, Gerhard , Hanson, Kimberly E. , Harrington, Amanda, Hayden, Randall T. , Hubka, Vít , Johnson, Kristie, Li, Ruoyu , Lanternier, Fanny , Leal, Sixto M. , Lee, Francesca , Luethy, Paul M. , Kwon‐Chung, Kyung J., Palavecino, Elizabeth , Pancholi, Preeti , Pappas, Peter G. , Procop, Gary W. , Rhoads, Daniel D. , Riedel, Stefan , Stevens, Bryan S. , Sullivan, Kaede Ota, Vergidis, Paschalis , Roilides, Emmanuel , Seyedmousavi, Amir, Tao, Lili , Vicente, Vânia Aparecida , Vitale, Roxana G. , Wengenack, Nancy L. , Westblade, Lars F. , Wiederhold, Nathan P. , White, Lewis, Wojewoda, Christina , Babady, N. Esther , Seyedmousavi, Seyedmojtaba , de Hoog, Sybren , Walsh, Thomas J , Ahmed, Sarah A , Alastruey-Izquierdo, A , Arendrup, Maiken Cavling , Borman, Andrew , Groll, Andreas H , Hanson, Kimberly , Hayden, Randall T , Hoenigl, Martin , Kus, Julianne V , Meis, Jacques F , Leal, Sixto M , Lockhart, Shawn R. , Luethy, Paul , Kwon-Chung, Kyung J , Nguyen, M Hong , Pancholi, Preeti , Procop, Gary W , Rhoads, Daniel D , Riedel, Stefan , Vergidis, Paschalis , Vitale, Roxana G , Wengenack, Nancy L , White, Lewis , Wojewoda, Christina M , Zhang, Sean X , Cornely, Oliver A , Roilides, Emmanuel , Wiederhold, Nathan , Bai, Feng‐Yan , Chowdhary, Anuradha , Clark, Andrew, Dingle, Tanis C. , Dufresne, Philippe J. , Gangneux, Jean‐Pierre , Guillot, Jacques , Hawksworth, David L. , Hoenigl, Martin , Kus, Julianne V. , Lackner, Michaela , Martin, Isabella W. , Meyer, Wieland , Ostrosky‐Zeichner, Luis , Redhead, Scott A. , Stevens, Bryan, Wang, Qiming , Zhang, Sean X.

Mayo Clinic

Journal of Clinical Microbiology | October 26, 2023 | Volume: 61 | Issue: 11 | Pages: No page available

10.1128/jcm.00873-23 | PMID 37882528 Get It

ABSTRACT The rapid pace of name changes of medically important fungi is creating challenges for clinical laboratories and clinicians involved in patient care. We describe two sources of name change which have different drivers, at the species versus the genus level. Some suggestions are made here to reduce the number of name changes. We urge taxonomists to provide diagnostic markers of taxonomic novelties. Given the instability of phylogenetic trees due to variable taxon sampling, we advocate to maintain genera at the largest possible size. Reporting of identified species in complexes or series should where possible comprise both the name of the overarching species and that of the molecular sibling, often cryptic species. Because the use of different names for the same species will be unavoidable for many years to come, an open access online database of the names of all medically important fungi, with proper nomenclatural designation and synonymy, is essential. We further recommend that while taxonomic discovery continues, the adaptation of new name changes by clinical laboratories and clinicians be reviewed routinely by a standing committee for validation and stability over time, with reference to an open access database, wherein reasons for changes are listed in a transparent way.
Neuropathologic evaluation of cerebrovascular disease in patients with rheumatoid arthritis
Larsen, Rachel A. , Constantopoulos, Eleni , Kodishala, Chanakya , Lovering, Edward , Hulshizer, Cassondra A., Lennon, Ryan J. , Crowson, Cynthia S. , Nguyen, Aivi T. , Myasoedova, Elena , Crowson, CS , Myasoedova, Elena , Nguyen, Aivi T , Kumar, Rakesh

Mayo Clinic

Rheumatology | October 23, 2023 | Volume: 62 | Issue: SI3 | Pages: SI296-SI303

10.1093/rheumatology/kead396 | PMID 37871918 Get It

Abstract Objectives Active RA has been associated with an increased risk of both cardiovascular and peripheral vascular disease. We aimed to compare cerebrovascular changes in patients with and without RA, both with and without a neuropathologic diagnosis of neurodegenerative disease. Methods Patients with RA (n = 32) who died and underwent autopsy between 1994 and 2021 were matched to non-RA controls (n = 32) on age, sex and level of neurodegenerative proteinopathy. Routine neuropathologic examination was performed at the time of autopsy. Cerebrovascular disease severity was evaluated using modified Kalaria and Strozyk scales. Clinical dementia diagnoses were manually collected from patients’ medical records. Results Prior to death, 15 (47%) RA patients and 14 (44%) controls were diagnosed with dementia; 9 patients in each group (60% and 64%, respectively) had Alzheimer’s disease. The prevalence of cerebral amyloid angiopathy, microinfarcts, infarcts or strokes was found to be similar between groups. Patients with RA were more likely to have more severe vascular changes in the basal ganglia by Kalaria scale (P = 0.04), but not in other brain areas. There were no significant differences in the presence of large infarcts, lacunar infarcts or leukoencephalopathy by Strozyk scale. Among patients with RA and no clinical diagnosis of dementia, the majority had mild–moderate cerebrovascular abnormalities, and a subset of patients had Alzheimer’s disease neuropathologic changes. Conclusion In this small series of autopsies, patients with and without RA had largely similar cerebrovascular pathology when controlling for neurodegenerative proteinopathies, although patients with RA exhibited more pronounced cerebrovascular disease in the basal ganglia.
Stent-assisted Woven EndoBridge device for the treatment of intracranial aneurysms: an international multicenter study
Diestro, Jose Danilo Bengzon , Adeeb, Nimer , Regenhardt, Robert W. , Guenego, Adrien , Lay, Sovann V. , Balushi, Ali Al , Premat, Kévin , Namaani, Kareem El, Möhlenbruch, Markus , Foreman, Paul M. , Vachhani, Jay A. , Župančić, Vedran , Rai, Hamid, Tutino, Vincent M. , Mirshahi, Shervin , Ghozy, Sherief , Rabinov, James D. , Ren, Yifan , Goren, Oded , Michelozzi, Caterina , Elens, Stéphanie , Starke, Robert M. , Nguyên, Anh , Jones, Jesse , Psychogios, Marios, Spears, Julian , Marotta, Thomas R. , Bres-Bullrich, Maria , Mayich, Michael , Salem, Mohamed M. , Burkhardt, Jan‐Karl , Jankowitz, Brian T. , Ulfert, Christian , Lubicz, Boris , Puri, Ajit S , Pero, Guglielmo , Asadi, Hamed , Ducruet, Andrew F. , Albuquerque, Felipe C , Patel, Nirav J. , Kan, Peter , Kalousek, Vladimir , Lylyk, Pedro , Boddu, Srikanth , Stapleton, Christopher J. , Knopman, Jared , Tjoumakaris, Stavropoula , Clarençon, Frédéric , Patel, Aman B. , Tawk, Rabih, Ghozy, Sherief , Diestro, Jose Danilo B , Shotar, Eimad , Tutino, Vincent M , Nguyen, Anh , Pero, Guglielmo , Kalousek, Vladimir , Regenhardt, Robert W , Ulfert, Christian , Lay, Sovann V , Burkhardt, Jan‐Karl , Dibas, Mahmoud , Vranic, Justin E. , Renieri, Leonardo , Shotar, Eimad , Saliou, Guillaume , Lylyk, Iván , Hafeez, Muhammad Ubaid , Rutledge, Caleb , Harker, Pablo , Alotaibi, Naif M. , Schirmer, Clemens M. , Piano, Mariangela , Kühn, Anna Luisa , Hassan, Ameer E , Salehani, Arsalaan , Psychogios, Marios‐Nikos , Mendes Pereira, Vitor , Parra-Fariñas, Carmen , Bullrich, María Bres , Domingo, Ricardo A. , Huynh, Thien , Tawk, Rabih G. , Panni, Pietro , Griessenauer, Christoph J. , Siddiqui, Adnan H. , Jabbour, Pascal , Limbucci, Nicola , Aziz‐Sultan, Mohammad Ali , Cuellar, Hugo , Cognard, Christophe , Dmytriw, Adam A.

Mayo Clinic

Journal of Neurosurgery | October 21, 2023 | Volume: 140 | Issue: 4 | Pages: 1071-1079

10.3171/2023.8.jns235 | PMID 37862717 Get It

OBJECTIVE The Woven EndoBridge (WEB) device is an intrasaccular flow disruptor designed for wide-necked bifurcation aneurysms. These aneurysms may require the use of a concomitant stent. The objective of this study was to determine the clinical and radiological outcomes of patients undergoing stent-assisted WEB treatment. In addition, the authors also sought to determine the predictors of a concomitant stent in aneurysms treated with the WEB device. METHODS The data for this study were taken from the WorldWideWEB Consortium, an international multicenter cohort including patients treated with the WEB device. Aneurysms were classified into two groups based on treatment: stent-assisted WEB and WEB device alone. The authors compared clinical and radiological outcomes of both groups. Univariable and multivariable binary logistic regression analyses were performed to determine factors that predispose to stent use. RESULTS The study included 691 intracranial aneurysms (31 with stents and 660 without stents) treated with the WEB device. The adequate occlusion status did not differ between the two groups at the latest follow-up (83.3% vs 85.6%, p = 0.915). Patients who underwent stenting had more thromboembolic (32.3% vs 6.5%, p < 0.001) and procedural (16.1% vs 3.0%, p < 0.001) complications. Aneurysms treated with a concomitant stent had wider necks, greater heights, and lower dome-to-neck ratios. Increasing neck size was the only significant predictor for stent use. CONCLUSIONS This study demonstrates that there is no difference in the degree of aneurysm occlusion between the two groups; however, complications were more frequent in the stent group. In addition, a wider aneurysm neck predisposes to stent assistance in WEB-treated aneurysms.